Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up

被引：0

作者：

Fox, Edward ^{[1
]}

Arnold, Douglas ^{[2
]}

Cohen, Jeffrey ^{[3
]}

Coles, Alasdair ^{[4
]}

Confavreux, Christian ^{[5
]}

Hartung, Hans ^{[6
]}

Havrdova, Eva ^{[7
]}

Selmaj, Krzysztof ^{[8
]}

Weiner, Howard ^{[9
]}

Twyman, Cary ^{[10
]}

Vladic, Anton ^{[11
]}

Margolin, David ^{[12
]}

Oyuela, Pedro ^{[12
]}

Panzara, Michael ^{[12
]}

Compston, Alastair ^{[13
]}

机构：

[1] Univ Texas Med Branch, Round Rock, TX USA

[2] McGill Univ, Montreal, PQ, Canada

[3] Cleveland Clin, Solon, OH USA

[4] Addenbrookes Hosp, Cambridge, England

[5] Univ Lyon 1, F-69365 Lyon, France

[6] Univ Dusseldorf, Dusseldorf, Germany

[7] Charles Univ Prague, Sch Med 1, Prague, Czech Republic

[8] Klin J Katedra Neurol Akad, Lodz, Poland

[9] Brigham & Womens Hosp Ctr, Boston, MA USA

[10] Associates Neurol, Lexington, KY USA

[11] Sveti Duh Gen Hosp, Zagreb, Croatia

[12] Genzyme Corp, Cambridge, MA USA

[13] Univ Cambridge, Cambridge, England

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S41001

引用

页数：2

共 50 条

[21] Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study
Arnold, D. L.
Barnett, M.
Comi, G.
Giovannoni, G.
Pelletier, D.
Rovira, A.
Schippling, S.
Van Wijmeersch, B.
Margolin, D. H.
Thangavelu, K.
Traboulsee, A.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 329 - 329
[22] Patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy demonstrate durable improvements in clinical outcomes with alemtuzumab-5-year follow-up of CARE-MS II
Alroughani, Raed
Al Jumah, Mohamed
Arnold, Douglas L.
Hartung, Hans-Peter
Havrdova, Eva
Inshasi, Jihad Said
Margolin, David H.
Kasten, Linda
Compston, D. Alasdair S.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP9 - NP9
[23] Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study)
Inshasi, Jihad Said
Boyko, Alexey N.
De Seze, Jerome
Hartung, Hans-Peter
Havrdova, Eva
McCombe, Pamela
Montalban, Xavier
Pozzilli, Carlo
Vermersch, Patrick
Margolin, David H.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP11 - NP11
[24] Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up
Oreja-Guevara, Celia
Alroughani, Raed
Brassat, David
Boyko, Alexey N.
McCombe, Pamela
Steingo, Brian
Van Wijmeersch, Bart
Margolin, David H.
Thangavelu, Karthinathan
Rodriguez, Claudio E.
Vermersch, Patrick
NEUROLOGY, 2017, 88
[25] Lymphocyte counts and efficacy outcomes after alemtuzumab in relapsing remitting multiple sclerosis patients: the CARE-MS studies
Sorensen, P. S.
Arnold, D. L.
Cohen, J. A.
Fox, E. J.
Hartung, H. -P.
Havrdova, E.
Selmaj, K.
Weiner, H.
Palmer, J.
Margolin, D. H.
Panzara, M. A.
Compston, D. A. S.
Coles, A. J.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 207 - 208
[26] Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study
Soelberg-Sorensen, Per
Arnold, Douglas
Cohen, Jeffrey
Coles, Alasdair
Confavreux, Christian
Fox, Edward
Hartung, Hans
Havrdova, Eva
Selmaj, Krzysztof
Weiner, Howard
Miller, Tamara
Twyman, Cary
Lake, Stephen
Margolin, David
Richards, Susan
Sung, Crystal
Panzara, Michael
Compston, Alastair
NEUROLOGY, 2013, 80
[27] Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)
Oreja-Guevara, C.
Alroughani, R.
Brassat, D.
Boyko, A. N.
McCombe, P.
Steingo, B.
Van Wijmeersch, B.
Margolin, D. H.
Thangavelu, K.
Rodriguez, C. E.
Vermersch, P.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 648 - 649
[28] Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study
Arnold, Douglas L.
Barnett, Michael
Comi, Giancarlo
Giovannoni, Gavin
Pelletier, Daniel
Rovira, Alex
Schippling, Sven
Van Wijmeersch, Bart
Margolin, David H.
Thangavelu, Karthinathan
Traboulsee, Anthony
NEUROLOGY, 2017, 88
[29] Efficacy and safety of alemtuzumab in 113 patients with active relapsing-remitting MS: one-year follow-up in France
Ayrignac, Xavier
Collongues, Nicolas
De Seze, Jerome
Vermersch, Patrick
Biotti, Damien
Brassat, David
Vukusic, Sandra
Durand-Dubief, Francoise
Edan, Gilles
Lepage, Emmanuelle
Deburghgraeve, Veronique
Maillart, Elisabeth
Papeix, Caroline
Alla, Philippe
Berger, Eric
Bourre, Bertrand
Casez, Olivier
Pittion, Sophie
Debouverie, Marc
Theaudin, Marie
Derache, Nathalie
Defer, Gilles
Gout, Olivier
Deschamps, Romain
Tourbah, Ayman
Zagnoli, Fabien
Ruet, Aurelie
Ouallet, Jean
Brochet, Bruno
Manchon, Eric
Moreau, Thibault
Fromont, Agnes
Clavelou, Pierre
Guennoc, Anne Marie
Camdessanche, Jean-Phillippe
Carpentier, Antoine
Coman, Irene Antoanela
Audoin, Bertrand
Pelletier, Jean
Magy, Laurent
Ciron, Jonathan
Wiertlevski, Sandrine
Laplaud, David
De Broucker, Thomas
Frenay, Christine Lebrun
Cohen, Mikael
Labauge, Pierre
NEUROLOGY, 2017, 88
[30] Alemtuzumab efficacy and safety were maintained over 8 years in relapsing-remitting multiple sclerosis patients with highly active disease from CARE-MS I: TOPAZ study follow-up
Limmroth, V.
Achiron, A.
Bass, A. D.
Bertolotto, A.
Brandes, D.
Chinea, A.
Garcia, J. R.
Naismith, R. T.
Schippling, S.
Sharrack, B.
Sousa, L.
Tintore, M.
Traboulsee, A.
Uitdehaag, B. M. J.
Ziemssen, T.
Choudhry, Z.
Daizadeh, N.
Pelletier, D.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 535 - 536

← 1 2 3 4 5 →